Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2013

View Archived Issues

Tankyrase and/or Wnt signaling inhibitors designed at Novartis

Genetically engineered mouse model of pancreatic cancer developed

Shionogi reviews highlights of third quarter of fiscal 2012

Santen Pharmaceutical presents novel PARP inhibitors for ocular disorders

Microbiotix presents novel agents for bacterial infections

Eli Lilly patents new agents for sleep disorders

Mouse model allows testing of therapies targeting the human HTT gene

European decentralized registration procedure completed for BLI-800

ProtAffin Biotechnologie prepares new mutant polypeptides for cancer

Transgene divulges new mutant HBV polypeptides

Researchers at Glenmark Pharmaceuticals disclose novel monoclonal antibodies

New cholera vaccines presented by researchers in the U.S. and Bangladesh

Apocept receives FDA orphan drug designation and enters phase I study

Cerium oxide nanoparticles reduce ovarian cancer tumor growth in mice

Transgenic medaka model developed for screening drugs targeting oncogenes

Omeros reports toxicology study data for MASP-2 inhibitor

Bristol-Myers Squibb decides to stop development of analgesic

Eli Lilly discontinues clinical trials of tabalumab in RA

EMA grants accelerated assessment to trametinib application

Pergamum and Cadila Pharmaceuticals enter strategic collaboration

MSDC receives award from The Michael J. Fox Foundation

biOasis' Transcend-Herceptin conjugate shows promising antitumor activity

Dyax and CVie Therapeutics sign agreement for Kalbitor

Venaxis signs agreement with EMELCA Bioscience for E.U. launch of novel appendicitis test APPY1

Avexxin cleared to conduct study of AVX-001 in Denmark

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...